17
17
88 Welcome to the Center for Targeted Therapeutics and Translational Nanomedicine
21 1bCT3N is a joint interdisciplinary venture between the Perelman School of Medicine (PSOM) and the School of Engineering and Applied Science (SEAS), with the mission to facilitate and accelerate translational research in targeted therapeutics and nanomedicines by bringing together the many leading laboratories active in these areas at the University of Pennsylvania, CHOP and surrounding academic institutions. Research areas being pursued by CT3N faculty include design of biomaterials and carriers for drug delivery, identification of molecular targets for cell-specific delivery, studies of targeting, binding, sub-cellular trafficking and metabolism of targeted drugs.
48 672
2025 CT3N Symposium
41"Targeting the CNS"
Hold the date: December 3, 2025
c4
Missed the 2024 CT3N Symposium?
View the recordings here
6
39
CT3N Faculty Publication Highlights
23Wang et al., Cell (2025)
69
Patel et al., Nature Commun. (2025) / Jake Brenner lab
6c
57 21 21 25 49 5 25 49 25 1f 1f 49 45 21 3b 21 25 1d
Upcoming Events
a a f a 81 1 18Faculty in the News
9 2971 65 Microrobots Navigate Diverse Oral Environments to Deliver Therapies (Daeyeon Lee; Hyun Koo) a 7
3dThursday, April 24, 2025
2a54 30 Christopher Murray Elected AAAS Fellow a 7
3dThursday, March 27, 2025
2a6c 62 New technology is poised to bring gene therapy to common chronic diseases (Jake Brenner) a 7
3cTuesday, March 25, 2025
2a70 64 Four Penn cancer researchers elected as 2025 Fellows of the AACR Academy (Garrett Brodeur) a 7
3bMonday, March 10, 2025
2a5e 45 New mRNA therapy could repair damaged lungs (Virgil Percec) a 7
3eFriday, February 21, 2025
3f42 More News 15
15Featured Faculty
94
Noor Momin, PhD, Assistant Professor, Department of Bioengineering, School of Engineering and Applied Science
3a2Dr. Noor Momin is the Stephenson Foundation Term Assistant Professor of Innovation. She completed her Bachelor of Science degree in Biomedical Engineering at the University of Texas at Austin and earned her Ph.D. in Biological Engineering. As a graduate student, Dr. Momin engineered a localization strategy that improves the safety and effectiveness of cytokine therapies used for cancer treatment. This technology is being evaluated in both canine and human clinical trials. She went on to conduct postdoctoral training at Massachusetts General Hospital where she examined the role of leukocytes in arrhythmia. In January of 2024, Dr. Momin launched her independent research group at University of Pennsylvania in the Bioengineering Department and the Penn Center for Precision Engineering for Health. The Momin lab seeks to understand and modulate the immune response for targeted treatment of cardiovascular diseases.
6f